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ABSTRACT
Introduction: The global epidemic of diabetes has led to an epidemic of diabetes complications. 
Diabetic neuropathy is the most common microvascular complication, of which diabetic peripheral 
neuropathy (DPN) and autonomic neuropathy (AN) are the most prevalent, affecting ~50% of patients. 
DPN results in pain with a poor quality of life and a loss of sensation with an increased risk of foot 
ulceration. Autonomic neuropathy can cause significant morbidity in a minority and is associated with 
increased mortality. The cornerstone of treatment to prevent or limit the progression of DPN/AN is 
multifactorial risk factor modification including treatment of glycemia, lipids and blood pressure. Whilst, 
there are no FDA-approved disease-modifying therapies, there are a number of therapies to relieve 
symptoms in DPN and AN.
Areas covered: The authors discuss current approved therapies for painful diabetic neuropathy and 
autonomic neuropathy. They also address the potential role of improving risk factors to limit the 
development and progression of diabetic neuropathy and new pathogenetic and pain-relieving 
treatments.
Expert opinion: The FDA-approved Pregabalin and Duloxetine over 25 years ago and Tapentadol, 6 
years ago for painful diabetic neuropathy. There are currently no FDA-approved disease-modifying 
treatments for diabetic neuropathy which has been attributed to inappropriate models of the disease 
with limited translational capacity and major limitations of trial designs and endpoints in clinical trials.
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1. Introduction
In 2017, the International Diabetes Federation estimated the 
prevalence of diabetes at 425 million people worldwide rising 
to 628 million by 2045 [1]. Diabetes has reached epidemic 
proportions worldwide and so has the burden from its com-
plications. Indeed, ~12% of global health expenditure is direc-
ted towards diabetes and its complications [1].
Diabetic neuropathy is a neurodegenerative disorder of 
peripheral nerves that preferentially targets sensory and auto-
nomic axons and later motor axons [2]. The most prevalent 
form is diabetic peripheral neuropathy (DPN), a distal, symme-
trical, length-dependent sensorimotor polyneuropathy. It is 
the primary cause of diabetic foot ulceration and non- 
traumatic amputations [3]. DPN manifests in a ‘stocking and 
glove’ distribution affecting the hands and lower limbs. The 
prevalence of DPN can be as high as 50% depending on age 
and type and duration of diabetes [4]. In Pirart’s now famous 
study initiated in the 1940s, the prevalence of DPN was 
assessed longitudinally over 25 years in 4400 patients [4]. 
Fifty percent of adults had DPN at 25 years which correlated 
with the duration of disease. However, recent studies show 
that DPN develops in adolescents. In the SEARCH for Diabetes 
in Youth Study [5], the prevalence of DPN was 7% in patients 
with type 1 diabetes and 22% in type 2 diabetes (age ≤20 
years with a duration of diabetes >5 years) [6]. Symptomatic 
painful DPN (pDPN) can affect up to one-third of people with 
diabetes [7] and is generally underreported by healthcare 
professionals [8,9]. It results in somnipathy, depression, poor 
quality of life and unemployment [10–13] and reduces 
a person’s ability to socially function.
Autonomic neuropathy is a diffuse neuropathy, which 
affects the cardiac, gastrointestinal, and genitourinary auto-
nomic plexus leading to cardiac autonomic neuropathy (CAN), 
gastrointestinal dysmotility, diabetic cystopathy, and erectile 
dysfunction, respectively. CAN is a silent but major contributor 
to mortality in patients with diabetes [14–17]. Based on the 
Diabetes Control and Complications Trial (DCCT)/ 
Epidemiology of Diabetes Interventions and Complications 
(EDIC) study, the prevalence of CAN in type 1 diabetes after 
15 years was close to 60% [18].
This review focuses on current treatment options for DPN, 
pDPN, and autonomic neuropathy.
1.1. Mechanism of peripheral nerve injury
The pathology of DPN is of a distal sensory predominant 
demyelination, axonal degeneration, and endoneurial 
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microangiopathy [19–21]. Hyperglycaemia activates several 
downstream metabolic cascades such as increased flux of 
the polyol pathway, enhanced advanced glycation end-pro-
duct formation, activation of protein kinase C, exaggerated 
oxidative stress and inflammation [19].
1.2. Pathogenetic therapies
Diabetic neuropathy is the strongest predictor of mortality in 
type 2 diabetes [22], and yet it remains the only microvascular 
complication of diabetes without a pathogenetic treatment 
[2]. Unfortunately, numerous pathogenetic treatments target-
ing the underlying molecular mechanisms have failed in phase 
2/3 clinical trials [23], including aldose reductase inhibitors, 
benfotiamine, protein kinase C inhibitors and C-peptide [24]. 
At present, there are no US Food and Drug Administration 
(FDA) approved disease-modifying treatments for DPN.
1.3. Endpoints for DPN
Endpoints recommended by health regulatory authorities 
such as the FDA and EMA including nerve conduction studies 
and quantitative sensory testing, targeting predominantly 
large nerve fibers have failed. Despite this, professional orga-
nizations such as the ADA and Neurodiab continue to endorse 
consensus guidance focused on symptoms, signs and nerve 
conduction and the monofilament [25]. Small nerve fibers are 
the earliest to degenerate and also have a large capacity for 
repair [26–29]. Robust quantification techniques like skin 
biopsy with assessment of intraepidermal nerve fiber density 
(IENFD) or corneal confocal microscopy with quantification of 
several corneal nerve parameters have now become available 
[30–32]. They represent a minimally invasive and completely 
non-invasive technique to monitor progression and repair in 
future clinical trials of DPN.
1.4. Glycemic control
Glycemic control is the only approach convincingly shown to 
prevent or delay the progression of neuropathy in patients 
with type 1 diabetes [33]. Callaghan et al [34] undertook 
a Cochrane Review of 17 randomized studies (type 1 diabetes: 
7 studies, type 2 diabetes: 8 studies, mixed etiology: 2 studies) 
and concluded that enhanced glucose control significantly 
prevented the development of clinical neuropathy and 
reduced nerve conduction and vibration threshold abnormal-
ities in type 1 diabetes. This conclusion was driven primarily by 
data from the Diabetes Control and Complications Trial (DCCT) 
and Epidemiology of Diabetes Interventions and 
Complications (EDIC) study which demonstrated benefit of 
early good glycemic control on DPN and CAN in type 1 
diabetes [14]. In the DCCT, the risk reduction for incident 
DPN with intensive glucose control was 64% after 6.5 years 
[14]. In the EDIC study, HbA1c in the standard and intensive 
treatment groups was similar by the fifth year (8.1% vs 8.2%); 
but the prevalence of DPN and CAN remained significantly 
lower in patients who had earlier intensive treatment during 
DCCT [35], demonstrating the concept of ‘metabolic memory’ 
[36]. Indeed, even in severe DPN in type 1 diabetes, complete 
normalization of glycemic control through pancreatic and 
kidney transplantation results in regeneration of small nerve 
fibers within 6 months followed by an improvement in symp-
toms and nerve conduction at 24 and 36 months, respec-
tively [37].
In type 2 diabetes, the evidence for improved glycemic 
control slowing down progression of neuropathy is less strong 
[38,39]. The Action to Control Cardiovascular Risk in Diabetes 
(ACCORD) showed no improvement in DPN after a follow-up 
of 5-year [39] and indeed there was an excess of mortality and 
hypoglycemia in those who were intensively treated [40]. 
Indeed, in the Cochrane analysis by Callaghan et al [34], 
enhanced glycemic control had a non-significant effect on 
sensory loss and no benefit on nerve conduction and vibration 
threshold abnormalities [34]. Thus, given the marginal bene-
fits, individualized glycemia targets will be appropriate for 
older patients to avoid increased risk of hypoglycemia and 
mortality [41].
1.5. Lipids
There is a robust body of data showing an association 
between plasma lipoproteins and triglycerides and the risk of 
DPN [42,43]. In an analysis of participants with mild to mod-
erate diabetic neuropathy, elevated triglycerides correlated 
with myelinated fiber density loss independent of disease 
duration, age and glycaemic control [43]. The Pittsburgh 
Epidemiology of Diabetes Complications Study also showed 
that high-density lipoprotein cholesterol was associated with 
DPN [44,45]. Cholesterol-lowering therapy in the form of sta-
tins and ezetimibe [46,47] and triglyceride lowering therapy in 
the form of fibrates [46] may reduce progression and severity 
of DPN. Well planned randomized trials are needed to 
Article highlights
● There is a major unmet clinical need for the treatment of diabetic 
polyneuropathy (DPN) and diabetic autonomic neuropathy (DAN). 
The mainstay of therapy to prevent or halt the progression of DPN 
and AN is multifactorial risk factor modification.
● There are no disease-modifying therapies and beyond multifactorial 
risk factor modification, symptomatic treatment remains the mainstay 
of the management of painful DPN (pDPN) and AN.
● FDA-approved therapies for the relief of neuropathic pain were 
empirically identified from centrally-acting drugs for depression 
(Duloxetine) and epilepsy (Gabapentin and Pregabalin). These drugs 
were not developed based on a neurobiological understanding of 
pDPN.
● Novel pharmacotherapies have putative superior efficacy and adverse 
events profile e.g., Mirogabalin has better relief of neuropathic pain 
and reduced somnolence. P2X3 antagonists targeted the cough 
hypersensitivity pathway may relieve neuropathic pain and clinical 
trials are eagerly awaited.
● A major unmet need in the development of disease modifying 
therapies is an easily accessible biomarker for diagnosing and mon-
itoring DPN. Corneal confocal microscopy is a rapid non-invasive 
method to visualise small nerve fibres to identify early neuropathy 
and assess treatment response.
Biomarkers to enrich clinical trials of patients with pDPN to 
increase the responder rate are required.
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evaluate the impact of lipid-lowering therapy on DPN. Statins 
may rarely induce an acute painful neuropathy in some indi-
viduals [48]. Alpha-lipoic acid, a potent antioxidant has shown 
favorable results with a reduction in neuropathic symptoms, 
but a limited impact on neurological deficits [49–51].
1.6. Renin-Angiotensin-Aldosterone System
A small open label study of lisinopril in hypertensive subjects 
(n=13) showed improvements in nerve conduction over 12 
weeks [52]. Subsequently, an RCT of trandolapril showed an 
improvement in nerve conduction, amplitude, and latency in nor-
motensive patients with mild diabetic neuropathy over 1 year [53]. 
Also, quinapril increased parasympathetic activity in patients with 
AN and had a sustained effect at 6 months [54] and 2 years [55]. It 
has been postulated that addressing the parasympathetic/sympa-
thetic imbalance may contribute to the reduction in the risk of 
malignant ventricular arrhythmias in AN [54].
1.7. Multifactorial Intervention
The STENO-2 study [56] in patients with type 2 diabetes and 
microalbuminuria showed that 4 years of intensive multifac-
torial treatment (weight, hyperglycemia, hypertension, dyslipi-
demia) slowed the progression of autonomic neuropathy in 
the 21-year follow-up analysis [57], but had no impact on DPN. 
However, the primary end point for DPN was the assessment 
of vibration perception, an imprecise and highly variable end- 
point.
1.8. Diet, lifestyle and weight loss
Weight loss may not only modulate insulin resistance leading to 
a remission of diabetes [58], but may also reverse DPN [30]. 
Intervention with diet and exercise in people with IGT using the 
Diabetes Prevention Programme (DPP) protocol (aim 5-7% 
weight loss) resulted in an increase in IENFD, improved neuro-
pathic pain and sural nerve amplitude [30]. Bariatric surgery 
results in reduced macrovascular disease and mortality [59] 
and an improvement in symptoms, signs, and small nerve fibers 
[60,61]. A meta-analysis of 4 studies of bariatric surgery showed 
an improvement in symptoms and signs with reductions in the 
neuropathy symptoms score (NSS) (ES = - 3.39, 95%CI: - 4.51 to -  
2.28, P< 0.0001) and neuropathy disability score (NDS) (ES = -  
0.63, 95%CI: - 1.12 to - 0.13, P<0.013) [62]. Importantly, acute 
neuropathies can occur after bariatric surgery due to micronu-
trient deficiencies [63,64] and need to be considered if there is 
an acute worsening of neuropathic symptoms.
1.9. Treatment of Painful DPN
In clinical practice the approach to alleviate the symptoms of 
pDPN is to try different therapies until one is successful or try 
a combination of therapies. A successful outcome is consid-
ered with moderate improvement (~30-50%) in pain and 
a >50% pain reduction is considered a good outcome [65]. 
FDA approved drugs for neuropathic pain with number 
needed to treat for benefit (NNTB) and number needed to 
treat for harm (NNTH) (Table 1) and NICE recommended 
treatment (Table 2) with adverse events for each therapy are 
provided. It must be noted that trials of drugs for neuropathic 
pain, including FDA-approved serotonin norepinephrine reup-
take inhibitors (SNRIs) and alpha 2 delta ligands lack long-term 
clinical trial efficacy and safety data [66] although this should 
not negatively impact their use as pDPN is a highly debilitat-
ing condition. Randomized clinical trials rarely extend beyond 
20 weeks in pDPN [66].
The prescription of medications for pDPN is agnostic in 
nature and lacks a mechanism-based approach. However, 
improved clinical phenotyping and targeting of therapies 
based on co-morbid conditions such as anxiety and depres-
sion may result in improved outcomes [67]. Superficial clinical 
phenotyping in relation to symptomatology has not been 
shown to improve the response to therapy [68]. However, 
more detailed phenotyping using quantitative sensory testing 
(QST) has shown promise with patients with an irritable noci-
ceptor (IN) (n=31) compared to a non-irritable nociceptor 
(n=52) phenotype showing a significantly greater response 
to oxcarbazepine by reducing the overall NNTB from 6.9 to 
3.9 [69]. The relative efficacy of 5% lignocaine was assessed in 
15 patients with IN and 25 patients with non-IN and showed 
a greater effect in those with IN, on pain paroxysms and deep 
aching pain [70]. There is preclinical evidence on rate- 
dependent depression (RDD) of the spinal H-reflex acting as 
a marker for spinal disinhibition in a subset of pDPN [71]. RDD 
may be a treatment response biomarker of spinally mediated 
pain to allow a personalized medicine approach in pDPN, 
specifically utilizing therapies such as SNRI’s that target des-
cending spinal inhibitory pathways [72].
The potential benefit and overall efficacy of pregabalin and 
duloxetine was studied in the COMBO-DN Study. This was 
a multi-national randomized double blind, parallel group trial 
to compare the efficacy and tolerability of high dose mono-
therapy (duloxetine 120mg/day or pregabalin 600mg/day) to 
standard dose combination therapy (duloxetine 60mg/day 
plus pregabalin 300mg/day) in patients with pDPN, resistant 
to standard dose monotherapy [73]. There were no significant 
difference in Brief Pain Inventory (BPI) in standard dose com-
bination therapy compared to high dose monotherapy ther-
apy in those not achieving adequate pain relief on standard 
dose duloxetine (60mg/day) or pregabalin (300mg/day) mono-
therapy [73]. However, in a secondary analysis of the initial 
monotherapy run-in phase, duloxetine (60mg/day) was super-
ior to pregabalin (300mg/day) at 8-weeks. Further, exploratory 
post hoc analyses of COMBO-DN showed that high-dose 
monotherapy was more favorable in patients with severe 
pain, whereas combination therapy was more beneficial in 
patients with moderate and mild pain [74].
1.10. Antidepressants
1.10.1. Tricyclic Antidepressants (TCAs)
TCAs are thought to indirectly modulate the opioid system in 
the brain via serotonergic and norepinephrine neuromodula-
tion, amongst other properties [75–77]. Careful dose titration 
is required over a period of 6-8 weeks before reasonable 
effects are noted, hence compliance may sometimes be com-
promised [78]. TCAs are first- or second-line recommendations 
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in all five international guidelines on pain management in 
pDPN, with most citing amitriptyline as the drug of choice 
amongst the TCAs. The recent 2017 diabetic neuropathy posi-
tion statement of the American Diabetes Association stated 
that TCAs should be used with caution given their higher risk 
profile, particularly in elderly populations or those with under-
lying cardiovascular disease [79]. The American Academy of 
Neurology, the American Association of Neuromuscular and 
Electrodiagnostic Medicine, and the American Academy of 
Physical Medicine and Rehabilitation published a joint state-
ment concluding that amitriptyline has the greatest efficacy 
amongst TCAs [80]. Studies have shown superior efficacy of 
imipramine, but there is insufficient evidence to advocate 
routine use [81].
Fluoxetine is FDA-approved treatment for pDPN. In one 
study, a trial of fluoxetine in patients who received relief 
from TCAs but resulted in withdrawal due to adverse effects 
suggested benefit from a trial of fluoxetine therapy [82]. 
However, a Cochrane Systematic Review of antidepressants 
for the treatment of neuropathic pain found a lack of data 
to support the use of Fluoxetine in pDPN [82].
1.11. Serotonin- Norepinephrine Reuptake Inhibitors 
(SNRIs)
Duloxetine has FDA approval for the treatment of pDPN. 
A Cochrane review of duloxetine which included 8 trials 
(n=2,728) showed that duloxetine 60mg/day was superior to 
placebo with a 50% pain reduction by 12 weeks (NNTB=5, 95% 
CI 4-9) [83]. Duloxetine has lower rates of anti-cholinergic side 
effects compared to amitriptyline resulting in a superior adverse 
events profile, but side effects include somnolence and consti-
pation [84]. A post hoc analysis of three pooled double blind, 
placebo-controlled trials evaluating the use of duloxetine in 
older patients (aged >65 years) advocates the safety and effi-
cacy of this drug in an older adult population [85].
Venlafaxine has shown efficacy in treating pDPN in 
a double blind placebo-controlled trial in which visual analo-
gue pain intensity scales were used as the primary outcome 
measure [86], but is not approved by the FDA for neuropathic 
pain. A Cochrane collaboration systematic review [82] of ven-
lafaxine for the treatment of neuropathic pain reported an 
NNTB of 3.1 (95% CI 2.2-5.1), which is comparable to amitripty-
line [87]. Venlafaxine has also shown superiority to duloxetine 
Table 1. FDA approved drugs for neuropathic pain in adults with their respective Dose Range, NNTB and NNTH.
Medication Dose Range in Adults NNTB (95% C.I)
Pain Reduction of at least: 30% 50% NNTH (95% C.I) Reference
Anti-Convulsants
Gabapentin 300-3600 mg/day NS 6.6  
(5.0-9.7)**
At least one AE** 7.5 (6.1-9.6) 
AE Withdrawal 30 (20-66)
[192,193]





Somnolence 9.5 (7.0-15), 
Dizziness 4.8 (3.9-6.2), AE 
leading to withdrawal 11 
(7.8-19)
600 mg/day:Somnolence 5.2 
(4.1-7.0), Dizziness 3.8 (3.2-4.9), 
AE Withdrawal 7.1 (5.3-11)
[194,195]
Lamotrigine 25-500 mg/day NS NS At least one AE 10 (6.5-27) 
Participants with a rash 27  
(16-89)***
[196,197]
Carbamazepine† 100-1200 mg/day NS 1.9  
(1.6-2.5)††





Morphine Titration dependent on pain 
severity






50-400 mg/day NS 4.4 (2.9-8.8) At least one AE 4.2 (2.8-8.3) 
AE Withdrawal 8.2 (5.8-14)
[104,203]




10-150 mg/day NS NS [206,207]
Desipramine 
hydrochloride
10-150 mg/day NS NS [208,209]
Serotonin/Norepinephrine Reuptake Inhibitors (SNRIs)
Duloxetine 30-120 mg/day 5 (3-7)‡ 5 (4-7)‡ AE leading to Withdrawal 18 (13-30) [83,210]
Selective Serotonin Reuptake Inhibitors (SSRI)




1-3 patches applied daily for 




1-4 patches for 30 minutes 
depending on the size of the 
treatment area on the feet
NS Achieved ≤90% of patch exposure time 77 (45-260)§ 
Dermal Irritation Score ≥ 2 at 2 hours 9.6 (7.7-13) 
Dermal Irritation Score ≥ 0 at 2 hours 4.5 (3.3-6.7)
[214,215]
* Gabapentin ≥1800 mg/day or Encarbil 1200 mg/day compared with placebo for pDPN ** Pregabalin 600mg/day compared with placebo for pDPN *** Includes 
participants with chronic neuropathic pain conditions other than pDPN and fibromyalgia † Carbamazepine is indicated as a first-line treatment for trigeminal 
neuralgia †† Adults with neuropathic pain treated with carbamazepine 100-2400 mg/day ‡ Adults with painful neuropathy or pDPN treated with 60 mg/day 
duloxetine § The number of participants with this outcome is small compared to the included total participants. AE = Adverse Event ER = Extended Release NNTB 
= Number Needed to Treat for Benefit NNTH = Number Needed to Treat for Harm NS = Not calculated or measurement combined with another variable 
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in some studies, however there is a lack of larger comprehen-
sive trials [87]. Venlafaxine must also be slowly weaned to 
reduce the potential for adverse events [88]. Desvenlafaxine, 
has been evaluated in a single randomized controlled trial and 
has shown some efficacy [89]
1.12. Anticonvulsants
Anticonvulsant medications have been used in the treatment 
of pDPN [90]. Cochrane reviews have shown limited efficacy 
with carbamazepine and oxcarbazepine in the treatment of 
pDPN, hence they are not recommended [91,92].
1.13. Alpha 2 Delta Ligands
Both gabapentin and pregabalin are commonly prescribed as 
first line agents for pDPN. Gabapentin is a lipophilic analogue of 
gamma-aminobutyric acid (GABA) that binds to the alpha 2/ 
Delta 1 subunit of the voltage-gated calcium channel on the 
presynaptic membranes and reduces excitability of chiefly glu-
taminergic neurons [93]. In a systematic review of 35 studies, 
gabapentin was found to be effective in reducing neuropathic 
pain (n=727), however, its effectiveness may be reduced if 
administered at low doses [94]. A meta-analysis of 21 trials 
compared the efficacy and safety of 6 agents for neuropathic 
pain and concluded that gabapentin provided a good balance 
between safety and efficacy for the treatment of pDPN [95].
Pregabalin is FDA approved for pDPN based on several 
robust-randomized control trials, which have all shown 
efficacy compared to placebo [96–98]. Furthermore, 
a comparative meta-analysis with other drugs found pregaba-
lin to be the most efficacious in reducing VAS pain scores [99]. 
Pregabalin promotes sleep whereas duloxetine showed 
increased sleep fragmentation in a placebo controlled trial 
evaluating the efficacy of pregabalin, amitriptyline and dulox-
etine [100]. Indeed somnolence is a common side effect of 
pregabalin and other studies have demonstrated an improve-
ment in sleep and quality of life in patients with pDPN 
[101,102]. Other side effects include edema and mood distur-
bance and pregabalin needs to be weaned as abrupt discon-
tinuation has been linked to seizures, cerebral edema and 
encephalopathy [103].
1.14. Opioid Analgesia
1.14.1. Partial Mu Receptor Agonists
A Cochrane review found that the efficacy of tramadol in 
neuropathic pain was determined in small studies with 
a potential risk of bias and concluded that there was insuffi-
cient data of adequate quality to provide convincing evidence 
that tramadol is effective in relieving neuropathic pain [104]. 
However, tramadol is recommended as 2nd or third line in 
pDPN, especially to treat break-through pain in combination 
with other neuropathic pain agents. However, one must be 
cautious when using tramadol in combination with TCAs and 
SNRIs due to the increased risk of serotonin syndrome with 
confusion, seizures, labile blood pressure and in extreme 
cases, coma, and death.
Table 2. NICE Recommended Drugs for Neuropathic Pain in Adults with Adverse Event Data [215,216].
Treatment
NICE 
Recommendation Common Adverse Events Serious Adverse Events Reference
Gabapentin 1-2 Dizziness, Fatigue, Somnolence, Dry mouth. Weight 
gain, Peripheral oedema, Headache
Angioedema, Hepatotoxicity, Rhabdomyolysis, Suicidal 
thoughts and behaviour, Ataxia, Seizures (after rapid 
discontinuation), Thrombocytopenia
[193]
Pregabalin 1-2 Somnolence, Dizziness, Ataxia, Fatigue Stevens-Johnson syndrome 
Suicidal thoughts and behaviour 
Seizures (after rapid discontinuation)
[195]
Duloxetine 1-2 Nausea, Somnolence, Dizziness, Constipation, 
Dyspepsia, Diarrhoea 
Dry mouth, Anorexia, 
Headache, Diaphoresis, Insomnia, Fatigue, Decreased 
libido
Severe hyponatremia, Stevens-Johnson syndrome, 
Seizures, Fragility bone fractures, Shift to mania 
(bipolar disorder), Hepatotoxicity, Suicidal thoughts 
and behaviour, Serotonin syndrome, Glaucoma, 
Hypertensive crisis, Cardiac arrhythmias, Neuroleptic 
malignant syndrome, Gastrointestinal 
Haemorrhage, Delirium, Myocardial infarction,
[83]
Amitriptyline* 1-2 Dry mouth, Fatigue, Headache, Dizziness, Insomnia, 
Orthostatic hypotension, Anorexia, Nausea, Urinary 
retention, Constipation, Blurred vision, Disturbance, 
Mydriasis, Weight gain, Somnolence
Bone marrow suppression, 
Delirium, Heart failure exacerbation, Strokes, 
Seizures, Hepatotoxicity, 
Suicidal thoughts and behaviour, Mania (bipolar 
disorder), Neuroleptic malignant syndrome, Serotonin 
syndrome, Severe hyponatremia, Cardiac arrhythmias, 
Conduction abnormalities, Myocardial infarction, 
Fragility bone fractures
[217]
Tramadol 3 Somnolence, Constipation, Nausea, Vomiting, Light- 
headedness, Dizziness
Respiratory depression, 






3 Burning, Stinging, Erythema 
Coughing, Sneezing***
No Data [219]
Recommendations are indicated as 1 = First Choice, 2 = Second Choice 3 = Third Choice. * The NNTB for amitriptyline is 5.1 (95% C.I 3.5-9.3), however this Includes 
participants with chronic neuropathic pain conditions other than pDPN at multiple dosages ** The NNT for 0.075% both 0.025% Capsaicin cream combined is 
reported as 8.1 (95% C.I 5.7-14) in participants with post-herpetic neuralgia and painful diabetic peripheral neuropathy *** Reporting of adverse events was 
inconsistent and incomplete in the included studies NICE = National Institute of Clinical Excellence 
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Modified release Tapentadol has been approved by the FDA for 
the treatment of neuropathic pain. A 12-week open label study in 
396 patients with pDPN demonstrated a 30% pain reduction in 
65% of patients and a 50% pain reduction in 34.9% of patients 
[105] and another 12 week study confirmed this data [106].
1.14.2. Opioid Agonists
A Cochrane Collaboration review of 31 studies evaluated the 
use of opioids in neuropathic pain. Shorter duration studies 
were found to provide only equivocal efficacy of opioids in 
reducing the intensity of neuropathic pain. The intermediate- 
term studies demonstrated significant efficacy of opioids over 
placebo however the results are likely to be subject to sig-
nificant bias due to drop out and small size of the stu-
dies [107].
1.14.3. Topical Medications
Topical treatments may be indicated where patients cannot 
tolerate conventional systemic therapies due to adverse 
events [108]. Furthermore, the risk of drug–drug interactions 
are also significantly reduced making topical therapies more 
attractive for a growing number of patients with multiple co- 
morbidities and polypharmacy.
Capsaicin is a transient receptor potential vanilloid 1 recep-
tor (TRPV1) agonist and is a naturally occurring alkaloid found 
in red chili peppers. A double blind placebo controlled trial 
(n=277) from the capsaicin study group found a significant 
reduction in pain using 0.0075% topical capsaicin as measured 
by physicians global evaluation and visual analog scales [109]. 
It is currently recommended as third line therapy in the UK’s 
NICE guidelines and second line by the American Academy of 
Neurology for the treatment of neuropathic pain. Patients 
frequently experience burning pain when it is applied, and 
compliance may be an issue as it needs to be applied four 
times daily.
The capsaicin 8% patch has an FDA label for neuropathic 
pain and can be applied every three months or as warranted 
by the return of pain [110,111]. In a large study, the 8% 
capsaicin patch reduced average daily pain scores and 
improved sleep interference scores after one application for 
30 minutes (n=186) compared to placebo (n=183), which were 
maintained for up to 12 weeks as measured by the Brief Pain 
Inventory (BPI) [112]. The capsaicin 8% group had a mean 
decrease in average daily pain score of 28% (SD 27.3%) com-
pared to the placebo group 21% (SD 29.4%) from baseline to 
weeks 2-12; p = 0.018 [112]. The capsaicin 8% patch is well 
tolerated with no deterioration over the course of a 52-week 
safety study as measured by the Norfolk Quality of Life- 
Diabetic Neuropathy (QOL-DN), Utah Early Neuropathy Scale 
(UENS), standardized sensory testing and reflex function [113]. 
One of the main concerns is that the application of even low 
dose capsaicin results in impaired thermal nociception and 
loss of intraepidermal nerves [114] which could increase the 
risk of diabetic foot ulceration.
In a systematic review of 38 studies, 5% Lidocaine patch 
was found to produce a significant pain reduction comparable 
to amitriptyline, capsaicin, gabapentin and pregabalin [108] 
and it has fewer and less clinically significant side effects 
compared to systemic agents [108].
Topical isosorbide dinitrate has shown a reduction in pain 
intensity in a double blind trial (n=22) [115]. Furthermore, 
a case series of 18 patients treated with glyceryl-trinitrate 
(GTN) patches showed a reduction in pain scores [116].. 
Topical lidocaine and GTN patches may be used in combina-
tion to provide 24-hour pain cover with alternating 12-hour 
application of each therapy.
1.14.4. Vitamin D
A number of studies have assessed the analgesic effect of 
vitamin D in pDPN in recent years [117–122]. Lower vitamin 
D correlates with increasing severity of neuropathic pain and 
increases thermal thresholds [123]. The NHANES study showed 
a clear association between vitamin D insufficiency (classified 
as a 25(OH)D <75 nmol/l) and pDPN [124]. In a study from 
Pakistan 141 patients with pDPN received a single high dose 
of intramuscular vitD3 (cholecalciferol 600,000IU) which 
resulted in ~70% reduction in pain scores [117] with additional 
improvements in quality of life (QoL), wellbeing and reduced 
emotional distress [125]. A recent meta-analysis showed an 
improvement in pain scores in favour of vitamin 
D supplementation (1.14 (95% CI = 1.22 to 1.67, p<0.0001) 
[126]. A large-scale RCT is required to determine the place of 
vitamin D in the treatment of pDPN.
1.15. Developmental treatments
We now consider a number of development therapies which are 
mainly in phase 2/3 clinical trials for the treatment of pDPN.
1.16. Nav Channel Antagonist
Voltage-gated sodium channels (NaV) present a potential ther-
apeutic target in the treatment of pDPN [127]. Both experi-
mental and clinical studies have suggested that 
polymorphisms and mutations in a number of pain-related 
genes are involved in the facilitation or inhibition of nocicep-
tion [127,128]. The current concept is that modulation of the 
ion channels expressed by certain genes may modify the 
neuropathic pain experience and the response to analgesics 
[127]. Voltage-gated sodium channel (Nav) genes hold most 
promise due to their key role in nociception and the patho-
genesis of small fiber neuropathies. Peripheral nociceptive 
neurons express a variety of sodium channel isoforms includ-
ing Nav1.3, Nav1.5, Nav1.7, Nav1.8, and Nav1.9, and each iso-
form plays a key role in the physiology of nociception [129].
The PROPANE study group suggested that underlying hyper-
excitability induced by the β2-subunit mutation (gain of function) 
of the Nav 1.7 channel may contribute to pDPN [128]. There are 
currently a number of potential molecules, which modulate this 
channel, but none have received marketing authorization. Of 
these Vixotrigine, a selective antagonist of NaV 1.7 is in phase 2 
trials for small fiber neuropathy and pDPN [128]. Unfortunately, 
trials in lumbosacral plexopathy and trigeminal neuralgia have 
failed to meet their primary outcome measure. There are also 
some positive data in phase 2 trials for VX-150 an inhibitor of 
NaV 1.8 channels in small fiber neuropathy (NCT03304522).
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1.16.1. Cibinetide
Cibinetide (ARA290) is a novel 11 amino acid non- 
hematopoietic peptide that interacts with high affinity and 
selectively with the innate repair receptor [130]. The innate 
repair receptor mediates tissue protection through activation 
of anti-inflammatory pathways [131]. Cibinetide has shown 
small improvement in glycemia and lipids and neuropathic 
symptoms as well as small fiber neuropathy detected with 
corneal confocal microscopy in a phase 2 study in diabetic 
neuropathy [132]. A further phase 2 study of Cibinetide in 
sarcoidosis confirmed regeneration of small nerve fibers with 
an improvement in neuropathic pain [133].
1.17. Trazadone plus Gabapentanoids
The separate but synergistic modulatory effects of polyphar-
macy may provide analgesic effect in combination therapy 
at much lower doses than each drug individually [134]. 
Trazodone is a second-generation antidepressant with 
strong sedative activity exerting its effects via 5-HT2, α1, and 
H1 blocking properties and inhibiting presynaptic uptake of 
serotonin [135]. It has been widely used as a hypnotic drug 
for decades in subtherapeutic antidepressant doses of 
100 mg or less [135] and its sedative effect is beneficial in 
disorders where somnipathy is a key feature [136,137]. In an 
uncontrolled open label 24 week study in fibromyalgia, tra-
zodone (50-300 mg/day) significantly improved pain severity 
and depression [135]. Combination with pregabalin (75- 
450 mg/day) further potentiated this improvement [135]. 
Forty-six percent of patients had a moderate-substantial 
decrease in pain scores [135]. There is currently a phase 2 
trial for pDPN comparing the efficacy of trazadone/gabapen-
tin combination in three doses (trazadone/gabapentin: 2.5/ 
25 mg, 5/50 mg, 10/100 mg) to gabapentin monotherapy 
and placebo (NCT03749642) [138].
1.17.1. Olodanrigan
Angiotensin 2 is an endogenous effector of the renin- 
angiotensin system and induces neuronal excitability at the 
dorsal root ganglion (DRG) [139]. Angiotensin 2 type 2 recep-
tor (AT2R) has been localized in cultured neurons of human 
and rat DRG [140]. Olodanrigan (EMA 401 or PD-126055) is an 
AT2R antagonist, which is being developed for the treatment 
of variety of pain conditions including neuropathic pain and 
pDPN [141]. Treatment with Olodanrigan has resulted in dose- 
related functional inhibition of capsaicin responses in a cell 
culture study [140]. In a phase 3 RCT of Olodanrigan in post-
herpetic neuralgia, 100 mg twice daily, a mean reduction in 
pain scores of −2.29 ± 1.75 was superior to placebo (−1·60 ± 
1·66, p=0.0066) at 28 days [142]. Olodanrigan was well toler-
ated and the adverse event rate was similar to placebo [142].
1.17.2. PL37
Opioids often constitute the mainstay of treatment for noci-
ceptive pain due to trauma, cancer, and inflammation, but 
limited efficacy for neuropathic pain in addition to depen-
dence makes them less attractive in the management of 
pDPN. Dual inhibitors of enkephalinases (DENKI) are a novel 
class of analgesics for chronic pain, which inhibit the activity of 
enkephalin-degrading enzymes peripherally, increasing the 
half-life and local concentration of enkephalins, potent endo-
genous analgesics [143,144]. Importantly, PL37 enhances the 
opioidergic pathway without resulting in dependence, there-
fore the abuse/misuse potential is low [143]. DENKI’s have 
been previously shown to produce antinociception in a rat 
sciatic nerve constriction model [145] and in experimental 
diabetic neuropathy [146]. Administration of PL37 in an 
experimental model of chemotherapy-induced neuropathy 
resulted in a reduction in neuropathic pain [144]. A phase 2 
placebo-controlled clinical trial of PL37 in addition to gaba-
pentin or pregabalin was completed in 2016 (EudraCT 
Number, 2013-004876-37), but the trial status is listed as ‘pre-
maturely ended’ and the results are yet to be published.
1.17.3. P2X3
P2X3 is a protein, which is encoded by the P2RX3 gene [147] 
and is a key sensory purinergic receptor in the peripheral 
nervous system responsible for irritation and pain. The P2X3 
receptor functions as a ligand-gated ion channel and trans-
duces ATP-evoked nociceptor activation. ATP signalling results 
in neuronal sensitization and neuropathic pain [148]. 
Gefapixant (MK-7264 or AF-219) and BLU-5937 are potent, 
selective P2X3 receptor antagonist and have been initially 
trialled (in phase 2/3 studies) as an antitussive therapy in 
refractory chronic cough [149]. P2X3 may have an effect on 
neuropathic pain and future trials in pDPN are expected [150].
1.18. Dextromethorphan/Quinidine combination (DMQ)
Dextromethorphan has multiple mechanisms of action includ-
ing as a non-selective serotonin reuptake inhibitor and 
a sigma-1 receptor agonist [151,152], the latter of which 
modulates calcium signaling in the central nervous system 
[153]. Quinidine is a class 1 anti-arrhythmic agent and acts as 
a Nav 1.5 channel inhibitor [154]. The combination of DMQ 
has been evaluated in two studies. In an early open label 
multi-center dose escalation study, where an incremental 
increase of 30/30mg to a maximal dose of 120/120mg 
showed an improvement in the pain intensity rating scale 
and pain relief rating scale [155]. In a further phase 3 RCT of 
pDPN (90 days), 379 patients with diabetes received either 
placebo (n=131), DMQ 30/30mg (n=125) or DMQ 45/30mg 
(n=123) and both dose combinations of DMQ were superior 
to placebo with significant improvements in the pain rating 
scale, pain intensity rating scale, sleep rating scale and activity 
rating scale [156].
1.19. Autonomic Neuropathy
The foundations of treatment for autonomic neuropathy are 
good glycemic control and cardiovascular risk management 
[157]. The DCCT showed that intensive glycemic control in 
patients with type 1 diabetes reduced the development of 
CAN by 45% [158]. Hypertension, obesity, hyperlipidemia, 
and smoking have been implicated in the development of 
CAN [39,159–163] and the STENO-2 trial showed that intensi-
fied multifactorial treatment in patients with type 2 diabetes 
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reduced the risk of CAN progression by 68% [164,165]. There 
are no FDA-approved disease-modifying treatments to reverse 
CAN. Initially there were favorable results for alpha-lipoic acid 
(ALA) on CAN [50]. However, more recently a study to evaluate 
triple anti-oxidant therapy (allopurinol (300mg qd), ALA 
(600mg bd) and nicotinamide (750mg bd)) in patients with 
type 1 diabetes and mild-moderate CAN found no benefit 
[166]. Lifestyle interventions, increased physical activity, β- 
adrenergic blockers, aldose reductase inhibitors, ACE inhibi-
tors, ARBs, and antioxidants have all shown benefit [167] but 
primarily in modulating sympathovagal imbalance in early 
disease rather than providing a mortality benefit in severe, 
symptomatic CAN. Patients with resting tachycardia or ortho-
static hypotension have substantial denervation and represent 
the severest end of the spectrum.
1.20. Orthostatic Hypotension (OH)
OH, can initially be managed with non-pharmacological treat-
ment which includes encouraging physical activity and exer-
cise to avoid deconditioning and fluid and salt repletion with 
a careful review of any medication which may exacerbate this 
condition. Fludrocortisone is effective however there are con-
cerns over supine hypertension, hypokalemia, congestive car-
diac failure and peripheral edema [168]. Midodrine is an FDA 
approved treatment for the management of orthostatic hypo-
tension. Droxidopa is an orally active synthetic precursor of 
norepinephrine and has recently been approved by the FDA 
for the treatment of symptomatic neurogenic orthostatic 
hypotension [169].
1.20.1. Gastroparesis
Gastroparesis is defined as the delayed removal of stomach 
contents in the absence of a physical obstruction [170]. The 
mainstay of treatment is dietary modifications, hydration, and 
improving glycemic control. Pharmacologic treatment with 
prokinetics can be used to increase gastric motility, However, 
their use is limited by side effects. Metoclopramide is the only 
drug approved by the FDA and EMA for short-term treatment 
of gastroparesis [171]. New therapies currently under investi-
gation include motilin receptor agonists, ghrelin receptor ago-
nists, and neurokinin receptor antagonists [172]. Mechanical 
options for intervention include transpyloric stenting, gastric 
electrical stimulation, and gastric per-oral endoscopic myot-
omy [172]. In severe intractable cases of gastroparesis laparo-
scopic pyloroplasty or gastrectomy may be options.
1.20.2. Diabetic Diarrhea
Diabetic diarrhea is a troublesome complication where the 
underlying mechanism is not fully understood [1]. The diag-
nosis depends on ruling out other causes of diarrhea. There 
are a number of options including anti-diarrheal agents, anti-
biotics to eradicate bacterial overgrowth, somatostatin analo-
gues, oral and topical clonidine, and selective serotonin 
5-hydroxy tryptamine type 3 (HT3) receptor antagonists 
[173,174].
1.20.3. Erectile Dysfunction (ED)
The incidence of ED is approximately three-fold higher in men 
with diabetes compared with the general population [175] 
and the prevalence varies from 35-75% [176]. In 
a comprehensive systematic review and meta-analysis of 145 
studies the prevalence of ED in diabetes was 52.5% (95% 
CI:48.8 – 56.2) [177]. The pathophysiology of ED in diabetes 
is multifactorial, consisting of both vascular, hormonal, and 
neurologic insults [175]. There are a number of therapeutic 
options for management of ED including phosphodiesterase 
type 5 (PDE5) inhibitors which remain the mainstay of initial 
therapy [178]. Avanafil, sildenafil, tadalafil, and vardenafil are 
all proven to be safe and effective for managing ED [179–185]. 
Additional treatments include testosterone replacement ther-
apy, intracavernosal injection therapy, vacuum constriction 
devices (VCDs), intraurethral prostaglandin suppositories and 
surgical placement of a penile prosthesis [178]. Multifactorial 
therapy is warranted in more complex cases which may 
include psychological intervention [178].
2. Expert Opinion
The pandemic of diabetes complications, particularly diabetic 
neuropathy demands early and effective therapy to prevent 
and treat this debilitating condition. Small fiber neuropathy 
occurs at the earliest stage of DPN and indeed it occurs in 
recently diagnosed T2DM and subjects with prediabetes. Small 
nerve fibers constitute the majority of axons in the peripheral 
nerve and are the earliest to be damaged and show repair 
even in advanced disease. The primary endpoint(s) for future 
clinical trials of drugs that target pathogenetic mechanisms 
should include a quantitative measure of small nerve fibers. 
Both skin biopsy, quantifying intra-epidermal nerve fibers, and 
corneal confocal microscopy (CCM), quantifying corneal nerve 
fibers represent ideal surrogate biomarkers and endpoints of 
DPN. CCM is non-invasive, reiterative, and readily lends itself 
to rapid quantification which increases its clinical utility sig-
nificantly [29,186]. The lack of treatments targeted at the 
pathogenesis of diabetic neuropathy is a major failure of the 
scientific community and in particular regulatory bodies such 
as the FDA and EMA, who continue to advocate the use of 
inappropriate large fiber endpoints for clinical trials. In parti-
cular, the FDA need to rapidly review the current status quo of 
so-called tried and tested endpoints such as symptoms, signs, 
and neurophysiology, which to date have failed to show ben-
efit in multiple clinical trials of DPN [25].
The need for sensitive and reiterative biomarkers for the early 
detection of neuropathy is paramount to developing valid 
screening programmes. As scientists working in the field of 
DPN, we look enviously to colleagues who research and manage 
people with retinopathy and nephropathy. They have simple 
but effective screening methods that detect subclinical pathol-
ogy [187]. This allows clinicians to instigate early intervention(s) 
based on individualized risk-based screening. By contrast, 
patients examined with the 10-g monofilament or 128Hz tuning 
fork will be missed even though they have mild DPN. There is an 
urgent need for individualized, risk-based screening for DPN. 
Additionally, there is no screening for CAN, despite it being 
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strongly associated with major cardiovascular events and mor-
tality [159]. Intensive control of cardiovascular risk factors can 
reduce the progression of CAN as shown by the Steno-2 studies 
and early recognition is imperative [188].
Symptomatic treatment of pDPN remains the mainstay for 
treating diabetic neuropathy. However, pDPN has a complex 
aetiology with both peripheral and central mechanisms. No 
single therapeutic agent is available which will target these 
multiple pathological processes, especially without unwanted 
central side effects. Pregabalin, gabapentin, TCAs and SNRIs 
are first-line therapies for treating pDPN, yet only 1 in 4 
patients will achieve a 50% improvement in pain. An increase 
in response rate will entail optimization of the pharmacoki-
netic and pharmacodynamic properties of neuropathic pain 
medication. This has been achieved recently with 
Mirogabalin, although at present it is only licenced in Japan 
[189,190]. Future RCTs should be directed to determine effi-
cacy of combination therapy versus well-established mono-
therapy. Other avenues to improve response rates include 
the development of pain biomarkers to determine therapeu-
tic response which would ideally predict optimal and indivi-
dualize pharmacological treatments. Two putative 
biomarkers of therapeutic response to neuropathic pain 
show promise. Functional Magnetic Resonance Imaging 
(fMRI) may provide brain-based biomarkers of pain [138]. 
A previous fMRI study showed that gabapentin suppressed 
the secondary mechanical hyperalgesia-evoked neural 
response in the descending pain modulatory system and 
suppressed resting state functional connectivity during cen-
tral sensitization, whereas, Ibuprofen showed no change 
when compared with placebo [191218]. Another, potential 
therapeutic response biomarker for pDPN and neuropathic 
pain is the rate-dependent depression (RDD) of the spinal 
H-reflex [72]. Loss of RDD indicates reduced descending inhi-
bitory pathway function which is augmented by SNRI’s such 
as Duloxetine. Thus, the detection of RDD may allow 
a personalized medicine approach to select either SNRI or 
non-SNRI-based neuropathic pain treatments.
Diabetic neuropathy screening demands tools, which are fit for 
purpose i.e. detect early disease. There is also an urgent need to 
utilise biomarkers with a greater ability to determine a therapeutic 
response for both disease-modifying and pain-relieving 
treatments.
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